What should I Know Regarding Pregnancy, Nursing and Administering Rid-A-Pain Tablet to Children or the Elderly?

If you are PREGNANT

  • No Known Fetal/Neonatal Risk:
  • FDA C (unknown human fetal risk; assess risk/benefit):
  • Contraindicated:
  • Contraindicated:
  • FDA C (unknown human fetal risk; assess risk/benefit):

If you are NURSING

  • Absolute Contraindication: ONE REPORT OF METABOL ACIDOSIS W/ASA;RISK OF REYE'S SYN W/VIRAL ILLNESS/FEVER
  • Precaution: HIGH DOSES MAY CAUSE HYPERACTIVITY AND WAKEFULNESS IN INFANT.
  • Absolute Contraindication: CNS/RESPIRATORY DEPRESSION,APNEA POSSIBLE;CAUTION W/ FAST CYP2D6 METABOLIZER
  • Absolute Contraindication: ONE REPORT OF METABOLIC ACIDOSIS; RISK OF REYE'S SYND IN VIRAL ILLNESS.
  • No Known Risk: LOW LEVELS EXCRETED WITH LOW RISK FOR ADVERSE EFFECTS IN INFANT

If you are an adult over 60

  • management or monitoring precaution: General-Elderly have a higher incidence of systemic toxicities. Dose reduction may be needed.
  • management or monitoring precaution: Pulmonary-Life threatening respiratory depression is more likely to occur with high doses, SR products, cachexia, or debilitation due to altered pharmacokinetics with poor fat stores, muscle wasting, or altered clearance. Monitor closely at initiation and with dose titration. Neuro/Psych-Risk for increased confusion and delirium. May increase fall risk. Avoid treatment with 3 or more CNS active drugs. Gastrointestinal-Constipation risk. Urogenital-Urinary retention risk.
  • management or monitoring precaution: Hepatic-Elderly may be more susceptible to hepatotoxicity. Strict adherence to a maximum daily dose is recommended, and the maximum dose recommendation varies between 3000-3800 mg depending on strength used and source of the recommendation.

Giving Rid-A-Pain Tablet to a child under 12

  • management or monitoring precaution: Use weight based dosing in children less than 12 years.
  • Severe Precaution: Contraindicated for pain management post-surgical tonsillectomy and or adenoidectomy. Respiratory depression and death reported in CYP2D6 ultra-rapid metabolizer patients post tonsillectomy or adenoidectomy. Avoid in patient with obesity, obstructive sleep apnea, asthma or other underlying breathing problem.
  • Contraindication: Increased risk of CNS and respiratory depression. Contraindicated age < 12 years. Respiratory depression and death reported in CYP2D6 ultra-rapid metabolizers post tonsillectomy or adenoidectomy. Risk increases with obesity, asthma, obstructive sleep apnea or other underlying lung or breathing problem.
  • Severe Precaution: Reye syndrome risk with viral illness, fever, and/or flu symptoms.
  • Severe Precaution: Do not use in viral illness due to possible increase risk of Reye syndrome.
  • management or monitoring precaution: Caution in infants with seizure disorder, cardiovascular disease, renal impairment, or hepatic impairment.

Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.

CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.